Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing population with myelodysplastic syndrome
4.1.2. Restraints
4.1.2.1. Side effects associated with the medications
4.1.3. Opportunity
4.1.3.1. Research and development of myelodysplastic syndrome drugs
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Treatment Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.1.2. Market Attractiveness Index, By Treatment Type
9.2. Stem Cell Transplant*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Immune Treatments
9.4. Chemotherapy
9.4.1. Hypomethylating Agents
9.4.1.1. Azacitidine (Vidaza)
9.4.1.2. Decitabine (Dacogen)
9.5. Immunomodulatory Drugs
9.5.1. Lenalidomide (Revlimid)
9.5.2. Others
9.6. Anti-anemics
9.6.1. Luspatercept-aamt (REBLOZYL)
9.6.2. Others
9.7. Others
9.7.1. Cytarabine (Cytosar-U)
9.7.2. Daunorubicin (Cerubidine)
9.7.3. Idarubicin (Idamycin)
9.7.4. INQOVI (ASTX727)
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Other End Users
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.5.1. The U.S.
11.2.5.2. Canada
11.2.5.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.5.1. Germany
11.3.5.2. The U.K.
11.3.5.3. France
11.3.5.4. Italy
11.3.5.5. Spain
11.3.5.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.5.1. Brazil
11.4.5.2. Argentina
11.4.5.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.5.1. China
11.5.5.2. India
11.5.5.3. Japan
11.5.5.4. Australia
11.5.5.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies
13. Company Profiles
13.1. AbbVie Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Accord Healthcare
13.3. Bristol-Myers Squibb
13.4. Jazz Pharmaceuticals Inc.
13.5. Novartis AG
13.6. Lupin Pharmaceuticals
13.7. Otsuka America Pharmaceutical Inc.
13.8. Onconova Therapeutics
13.9. Takeda Pharmaceutical Company Limited
13.10. Astex Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us